Accommodating vaccine preferences among women of childbearing age

TO THE EDITORS: After pregnant persons were excluded from the initial trials leading to emergency use authorizations for COVID-19 vaccines in the United States, Gray et al\(^1\) demonstrated robust vaccine-induced immune responses among pregnant women following COVID-19 messenger RNA (mRNA) vaccination (Pfizer-BioNTech and Moderna), with placental and breastmilk immune transfer to neonates. Unfortunately, rare clotting events following Janssen and AstraZeneca COVID-19 vaccination, which have been disproportionately experienced by women of childbearing age, have dampened the enthusiasm for these vaccines. At present, tailored education and vaccine deployment efforts should prioritize pregnant persons to mitigate newly recognized maternal and neonatal health risks following SARS-CoV-2 infection.\(^2\) Moreover, given the fundamental principles of self-determination, personhood, and patient autonomy that underlie informed consent, respecting patients’ right to make voluntary and informed healthcare decisions requires that all individuals should be fully informed about the risks and benefits of each vaccine, and—if feasible—provided a choice among the available COVID-19 vaccines.

Improving vaccine uptake among pregnant women is of heightened importance given recent evidence that pregnant women with SARS-CoV-2 infection have a considerably heightened risk of adverse maternal and neonatal health outcomes, including 22 times the risk of maternal mortality and twice the risk of both severe neonatal morbidity and perinatal morbidity and mortality than do pregnant women without SARS-CoV-2 infection.\(^2\) Reassuringly, we found that 70% of surveyed pregnant women in the United States would definitely or most likely obtain a COVID-19 vaccine as soon as possible.\(^3\) Understandably, the initial phase of the US vaccine rollout did not accommodate personal preferences among COVID-19 vaccines. However, in contrast to other countries with inadequate vaccine supplies or only 1 available vaccine, in the United States, 3 different COVID-19 vaccines are currently in supply that now exceed demand because of vaccine hesitancy and apathy. With newfound evidence of maternal and neonatal protection...
conferred by mRNA vaccines, increased risk of adverse health outcomes associated with SARS-CoV-2 infection among pregnant women, and disproportionate Janssen and AstraZeneca vaccine side effects among women of childbearing age, we strongly disagree with the recent suggestion that "health systems . . . should communicate to patients that they will receive, and only really need, one choice of vaccine." We believe that amid this public health crisis, these considerations necessitate that women of childbearing age be afforded a choice among COVID-19 vaccines to reduce elevated adverse vaccination side effects experienced by women of childbearing age, vaccine hesitancy, and the serious risks COVID-19 poses for pregnant women and their children.

References

1. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021;225:303.e1–17.

2. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection:
In vitro fertilization as an independent risk factor for placenta accreta spectrum

TO THE EDITORS: Salmanian et al\(^1\) discussed the possible effects of less physiological levels of estradiol on the risk of placenta accrete spectrum (PAS) development in in vitro fertilization (IVF) cycles, especially in frozen embryo transfer (FET) cycles, through manipulating the process of normal implantation and placentation. To date, the exact effect of altered levels of estradiol on endometrial microenvironment around the time of implantation remains uncertain. In this letter, we will explain one mechanism by which altered levels of estradiol could modulate the process of normal placentation.

The mechanism by which altered levels of estradiol affect the decidua formation and placentation could include immune response modulation. PAS pathophysiology involves thin decidua formation and excessive trophoblast invasion, both of which could be mediated by altered levels of cytokines that are otherwise required in controlled and balanced concentrations for normal decidua formation and trophoblast invasion (eg, interleukin 6 [IL-6], IL-8, and IL-1β).\(^2\) Previously, we have explained the possible role of less physiological levels of estradiol in preeclampsia development in artificial FET cycles through, at least in part, the modulation of various cytokines required for normal trophoblast invasion, including IL-6, IL-8, and IL-1β.\(^3\)

Thus, it is reasonable to think that less physiological levels of estradiol, such as that associated with IVF pregnancies, could lead to either augmented or less than required concentrations of these cytokines that might ultimately contribute to shallow (with subsequent ischemia and preeclampsia development), excessive trophoblast invasion or thin decidua formation (with future development of PAS).

However, the exact dosage of estradiol that could impair normal placentation remains inconclusive. In the literature, Kaser et al\(^4\) and Imudia et al\(^5\) have identified the potential cutoff of estradiol that could affect placentation, 732 pg/mL to predict PAS in cryopreserved embryo transfer in vitro fertilization pregnancies. Am J Obstet Gynecol 2021;225:466.e1–7.

Kaser DJ, Melamed A, Bormann CL, et al. Cryopreserved embryo transfer is an independent risk factor for plenta accreta. Fertil Steril 2015;103:1176–84.e2.

Imudia AN, Awonuga AO, Doyle JO, et al. Peak serum estradiol level during controlled ovarian hyperstimulation is associated with increased risk of small for gestational age and preeclampsia in singleton pregnancies after in vitro fertilization. Fertil Steril 2012;97:1374–9.

REFERENCES
1. Salmanian B, Fox KA, Arian SE, et al. In vitro fertilization as an independent risk factor for placenta accreta spectrum. Am J Obstet Gynecol 2020;223(5):68.e1–5.
2. Dimitriadis E, White CA, Jones RL, Salamonsen LA. Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update 2005;11:613–30.
3. Al-Lami RA, Sibai BM, Salih SM. Risk of preeclampsia in artificial cycles of frozen embryo transfer in vitro fertilization pregnancies. Am J Obstet Gynecol 2021;225:466.e1–7
4. Kramer DB, Opel DJ, Pardalis E, Mello MM. Choices in a crisis—individual preferences among SARS-CoV-2 vaccines. N Engl J Med 2021;384:e62.

© 2021 Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.ajog.2021.07.017